A Pilot Study for Ginkgolides Meglumine Injection Skin Testing.

NCT02264535 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

149

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergy

Interventions

DRUG: 0.1mg/ml Ginkgolides Meglumine Injection
DRUG: 1mg/ml Ginkgolides Meglumine Injection
DRUG: 5mg/ml Ginkgolides Meglumine Injection

Sponsor

Jiangsu Kanion Pharmaceutical Co., Ltd

Collaborators

[object Object]